AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,366.00p
   
  • Change Today:
    112.00p
  • 52 Week High: 13,276.00p
  • 52 Week Low: 9,725.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.62m
  • Volume: 1,006,644
  • Market Cap: £176,244m
  • RiskGrade: 123

AstraZeneca appoints Iskra Reic as vice-president of intl unit

By Frank Prenesti

Date: Wednesday 04 Dec 2024

LONDON (ShareCast) - (Sharecast News) - AstraZeneca said it had appointed AstraZeneca today announced the appointment of Iskra Reic as Executive Vice President (EVP), International with responsibility for overall strategy and driving sustainable growth across this broad region. This encompasses China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand. as executive vice-president of its international division with responsibility for overall strategy and driving sustainable growth across China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand.
Reic joined the Company in 2001 and most recently launched the company's vaccines and immune therapies unit in which she was responsible for the early and late-stage development of the pipeline and portfolio, including Covid-19 and RSV vaccines.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,366.00p
Change Today 112.00p
% Change 1.00 %
52 Week High 13,276.00p
52 Week Low 9,725.00p
Volume 1,006,644
Shares Issued 1,550.62m
Market Cap £176,244m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
93.77% below the market average93.77% below the market average93.77% below the market average93.77% below the market average93.77% below the market average
79.17% below the sector average79.17% below the sector average79.17% below the sector average79.17% below the sector average79.17% below the sector average
Price Trend
37.51% above the market average37.51% above the market average37.51% above the market average37.51% above the market average37.51% above the market average
51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average
Income
67.16% below the market average67.16% below the market average67.16% below the market average67.16% below the market average67.16% below the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average
Growth
85.66% above the market average85.66% above the market average85.66% above the market average85.66% above the market average85.66% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 15
Neutral 4
Sell 0
Strong Sell 0
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 20-Feb-25 08-Aug-24
Paid 24-Mar-25 09-Sep-24
Amount 210.00¢ 100.00¢

Trades for 01-Apr-2025

Time Volume / Share Price
16:28 0 @ 11,360.00p
16:18 2 @ 11,364.00p
16:17 1 @ 11,368.00p
16:13 0 @ 11,380.00p
16:06 0 @ 11,376.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page